Plus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% – What’s Next?

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) traded down 4.1% on Monday. The company traded as low as $0.6001 and last traded at $0.6427. 510,188 shares changed hands during trading, an increase of 338% from the average session volume of 116,506 shares. The stock had previously closed at $0.6699.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $51.75.

Plus Therapeutics Stock Up 19.0%

The stock’s 50-day moving average is $1.82 and its 200 day moving average is $4.41. The stock has a market capitalization of $4.67 million, a PE ratio of -0.29 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.43). The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.11 million. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. As a group, equities research analysts forecast that Plus Therapeutics, Inc. will post -3.76 EPS for the current year.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Citadel Advisors LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,597 shares of the company’s stock, valued at approximately $112,000. Citadel Advisors LLC owned about 0.37% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s research centers on treatments designed to deliver therapeutic radiation directly to tumors while limiting exposure to surrounding healthy tissue. Its lead investigational product is rhenium-186 nanoliposomes, also referred to as 186RNL or RNL. The candidate is being studied for recurrent glioblastoma and leptomeningeal metastases, a serious complication in which cancer spreads to the membranes surrounding the brain and spinal cord.